The authors studied the case records of 198 patients with FIGO stages I-II leiomyosarcoma of the corpus uteri to analyze the clinical, morphological, and biomolecular risk factors of its recurrence and metastasis. The rate of recurrence was 21.2% (42 cases), which occurred on an average of 27.7±4.9 months postoperatively. Deaths occurred 7.1±0.7 months after a recurrence. Its most significant clinical and morphological risk factors were the stage of the process (p=0.000004), FNCLCC high-grade malignant tumor (p=0.00005), more than one tumor nodule (p=0.0001), microcirculatory bed and peritumoral zone density values of more than 62.4±2.6 (p=0.0004), a tumor microcirculatory bed density value of less 70.6±3.6 (p = 0.003), more than 21.8±1.8% expression of the enzymes gyrase and topoisomerase IIα (p=0.000006), more than 16.6±1.3% expression of Ki-67 (p=0.00001), more than 22.1±2.1 AgNORs (p=0.00004), or more than 6.3±0.5% of cells in the S-phase of their cycle (p=0.001). There was no statistically significant relationship of the age of patients with leiomyosarcoma, the size of a tumor, its histological type, the type of HSP70 reaction, the receptor (progesterone and estrogen) status to tumor progression.